, Volume 16, Issue 5, pp 561–570 | Cite as

Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin

  • W. Pruzanski
  • D. W. Wilmore
  • A. Suffredini
  • G. D. Martich
  • A. G. D. Hoffman
  • J. L. Browning
  • E. Stefanski
  • B. Sternby
  • P. Vadas
Original Articles


Phospholipase A2 (PLA2) activity was measured in the serum of 23 individuals infused intravenously with endotoxin (EN) at a dose of 4 ng/kg body weight. A marked increase in PLA2 was noted 3 h after EN challenge (mean 828 ± 513 units/ml), reached its maximum at 24 h after the challenge (mean 2667 ± 2442 units/ ml), and was still evident at 48 h (mean 763 ± 366 units/ml). In contrast, TNF levels were maximal (mean 712 ± 375 pg/ml) 90 min after the EN challenge and subsided to very low values (5 ± 5 pg/ml) 5 h after the challenge. There was a positive correlation between the maximum response of TNF and that of PLA2 (r = 0.82,P < 0.01). Administration of ibuprofen or pentoxifylline did not alter the PLA2 response. EN challenge did not affect serum pancreatic PLA2 concentration or that of the lysosomal cationic enzyme, lysozyme. Neutralizing antibody against human recombinant (synovial type) PLA2 completely abolished PLA2 activity in the sera tested. We conclude that EN infusions cause marked intravascular release of nonpancreatic secretory PLA2 and that the magnitude of this response seems to be related to the prior generation of TNF.


Public Health Body Weight Internal Medicine Ibuprofen Lysozyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hesse, D. G., K. J. Tracey, Y. Fong, K. R. Manogue, M. A. Palladino, Jr., A. Cerami, G. T. Shires, andS. F. Lowry. 1988. Cytokine appearance in human endotoxemia and primate bacteremia.Surg. Gynecol. Obstet. 166:147–153.Google Scholar
  2. 2.
    Michie, H. R., K. R. Manogue, D. R. Spriggs, A. Revhaug, S. O'Dwyer, C. A. Dinarello, A. Cerami, S. M. Wolff, andD. W. Wilmore. 1988. Detection of circulating tumor necrosis factor after endotoxin administration.N. Engl. J. Med. 318:1481–1486.Google Scholar
  3. 3.
    Suffredini, A. F., R. E. Fromm, M. M. Parker, et al. 1989. The cardiovascular response of normal humans to the: administration of endotoxin.N. Engl. J. Med. 321:280–287.Google Scholar
  4. 4.
    Engelhardt, R., A. Mackensen, C. Galanos, andR. Andreesen. 1990. Biological response to intravenously administered endotoxin in patients with advanced cancer.J. Biol. Resp. Mod. 9:480–491.Google Scholar
  5. 5.
    Cannon, J. G., R. G. Tompkins, J. A. Gelfand, H. R. Michie, G. G. Stanford, J. W. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, et al. 1990. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.J. Infect. Dis. 161:79–84.Google Scholar
  6. 6.
    Engelhardt, R., A. Mackensen, andC. Galanos. 1991. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients.Cancer Res. 51:2524–2530.Google Scholar
  7. 7.
    Shalaby, M. R., A. Waage, L. Aarden, andT. Espevik. 1989. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo.Clin. Immun. Immunopathol. 53:488–498.Google Scholar
  8. 8.
    Martich, G. D., R. L. Danner, M. Ceska, andA. F. Suffredini. 1991. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents.J. Exp. Med. 173:1021–1024.Google Scholar
  9. 9.
    Van Zee, K. J., L. E. DeForge, E. Fischer, M. A. Marano, J. S. Kenney, D. G. Remick, S. F. Lowry, andL. L. Moldawer. 1991. IL-8 in septic shock, endotoxemia, and after IL-1 administration.J. Immunol. 146:3478–3482.Google Scholar
  10. 10.
    Danner, R. L., A. F. Suffredini, A. L. Van Dervort, M. Ceska, P. L. Stuetz, J. A. Zablotny, andE. A. Patterson. 1990. Detection of interleukin 6 (IL-6) and interleukin 8 (IL-8) during septic shock in humans.Clin. Res. 38:352A.Google Scholar
  11. 11.
    Vadas, P., andJ. B. Hay. 1983. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.Can. J. Physiol. Pharmacol. 61:561–566.Google Scholar
  12. 12.
    Vadas, P., W. Pruzanski, andE. Stefanski. 1988. Extracellular phospholipase A2: Causative agent in circulatory collapse of septic shock?Agents Actions 24:320–325.Google Scholar
  13. 13.
    Vadas, P., W. Pruzanski, E. Stefanski, L. G. Ellies, J. E. Aubin, A. Sos, andA. Melcher. 1991. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumor necrosis factor action.Immunol. Lett. 28:187–194.Google Scholar
  14. 14.
    Vadas, P., W. Pruzanski, E. Stefanski, B. Sternby, R. Mustard, J. Bohnen, I. Fraser, V. Farewell, andC. Bombardier. 1988. Pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse.Crit, Care Med. 16:1–7.Google Scholar
  15. 15.
    Stefanski, E., W. Pruzanski, B. Sternby, andP. Vadas. 1986. Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.J. Biochem. 100:1297–1303.Google Scholar
  16. 16.
    Sternby, B., andB. Akerstrom. 1984. Immunoreactive pancreatic colipase, lipase and phospholipase A2 in human plasma and urine from healthy individuals.Biochim. Biophys. Acta 789:164–169.Google Scholar
  17. 17.
    Osserman, E. F., andD. P. Lawlor. 1967. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia.J. Exp. Med. 124:921–952.Google Scholar
  18. 18.
    Pruzanski, W., andM. E. Platts. 1970. Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono and myelomonocytic leukemia.J. Clin. Invest. 49:1694–1708.Google Scholar
  19. 19.
    Beutler, B., N. Krochin, I. W. Milsark, C. Luedke, andA. Cerami. 1986. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance.Science 232:977–980.Google Scholar
  20. 20.
    Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. I. Fahey III,A. Zentella, andJ. D. Albert. 1986. Shock and tissue injury induced by recombinant human cachectin.Science 234:470–473.Google Scholar
  21. 21.
    Tracey, K. J., S. F. Lowry, T. J. Fahey III,J. D. Albert, Y. Fonc, D. Hesse, B. Beutler, K. R. Manogue, S. Galvano, H. Wei, A. Cerami, andG. T. Shirer. 1987. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.Surg. Gynecol. Obstet. 164:415–422.Google Scholar
  22. 22.
    Vadas, P., andJ. B. Hay. 1980. The release of phospholipase A2 from aggregated platelets and stimulated macrophages of sheep.Life Sci. 26:1721–1729.Google Scholar
  23. 23.
    Pruzanski, W., P. Vadas, andE. Stefanski. 1985. Activity of phospholipase A2 in sera and synovial fluids in arthritis.J. Rheumatol. 12:211–216.Google Scholar
  24. 24.
    Pruzanski, W., andP. Vadas. 1988. Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis.J. Rheumatol. 15:1601–1603.Google Scholar
  25. 25.
    Seilhamer, J. J., W. Pruzanski, P. Vadas, S. Plant, J. A. Miller, J. Kloss, andL. K. Johnson. 1989. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid.J. Biol. Chem. 264:5335–5338.Google Scholar
  26. 26.
    Kramer, R. M., C. Hession, B. Johansen, G. Hayes, P. McGray, E. P. Chow, R. Tizard, andR. B. Pepinsky. 1989. Structure and properties of a human nonpancreatic phospholipase A2.J. Biol. Chem. 264:5768–5775.Google Scholar
  27. 27.
    Pruzanski, W., P. Vadas, andV. Fornasier. 1986. Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits.J. Invest. Dermatol. 86:380–383.Google Scholar
  28. 28.
    Vadas, P., W. Pruzanski, J. Kim, andV. Fornasier. 1989. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2.Am. J. Pathol. 134:807–811.Google Scholar
  29. 29.
    Bomalaski, J. S., P. Lavton, andJ. L. Browning. 1991. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints.J. Immunol. 146:3904–3910.Google Scholar
  30. 30.
    Edelson, J. D., P. Vadas, J. Villar, J. B. Mullen, andW. Pruzanski. 1991. Acute lung injury induced by phospholipase A2. Structural and functional changes.Am. Rev. Respir. Dis. 143:11–20.Google Scholar
  31. 31.
    Sedor, J. R., T. W. Sedlak, K. Hornbuckle, W. H. Herman, andM. Konieczkowski. 1991. Inflammatory cytokines induce expression of a non-pancreatic (type II) mesangial cell phospholipase A2 mRNA in a highly regulated manner.J. Am. Soc. Nephrol. 1:481.Google Scholar
  32. 32.
    Oka, S., andH. Arita. 1991. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression.J. Biol. Chem. 266:9956–9960.Google Scholar
  33. 33.
    Chang, J., S. C. Gilman, andA. J. Lewis. 1986. Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: A possible signal for IL-1 action.J. Immunol. 136:1283–1287.Google Scholar
  34. 34.
    Chin, J. E., andY. Lin. 1988. Effects of recombinant human interleukin-1β on rabbit articular chondrocytes. Stimulation of prostanoid release and inhibition of cell growth.Arthritis Rheum. 31:1290–1296.Google Scholar
  35. 35.
    Suffys, P., F. Van Roy, W. Fiers. 1988. Tumor necrosis factor and interleukin 1 activate phospholipase in rat chondrocytes.FEBS Lett. 232:24–28.Google Scholar
  36. 36.
    Pfeilschifter, J., W. Pignat, F. Marki, andI. Wiesenberg. 1989. Release of phospholipase A2 activity from rat vascular smooth muscle cells mediated by cAMP.Eur. J. Biochem. 181:237–242.Google Scholar
  37. 37.
    Pfeilschifter, J., W. Pignat, K. Vosbeck, andF. Marki. 1989. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells.Biochem. Biophys. Res. Commun. 159:385–394.Google Scholar
  38. 38.
    Spriggs, D. R., M. L. Sierman, K. Imamura, M. Mohri, C. Rodriguez, G. Robbins, andD. W. Kufe. 1990. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor.Cancer Res. 50:7101–7107.Google Scholar
  39. 39.
    Mohri, M., D. R. Spriggs, andD. Kufe. 1990. Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells.J. Immunol. 144:2678–2682.Google Scholar
  40. 40.
    Bauldry, S. A., C. E. McCall, S. L. Cousart, andD. A. Bass. 1991. Tumor necrosis factor-α priming of phospholipase A2 activation in human neutrophils. An alternative mechanism of priming.J. Immunol. 146:1277–1285.Google Scholar
  41. 41.
    Revhaug, A., H. R. Michie, J. M. Manson, J. M. Waters, C. A. Dinarello, S. M. Wolff, andD. W. Wilmore. 1988. Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans.Arch. Surg. 123:162–170.Google Scholar
  42. 42.
    Kettelhut, I. C., W. Fiers, andA. L. Goldberg. 1987. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.Proc. Natl. Acad. Sci. U.S.A. 84:4273–4277.Google Scholar
  43. 43.
    Morton, A. R., P.Vadas, E.Stefanski, W.Pruzanski, and A.Pierratos. 1989. Increased levels of phospholipase A2 in renal failure patients. American Society of Nephrology 22nd Annual Meeting.Google Scholar
  44. 44.
    Vadas, P., W.Pruzanski, and V.Farewell. 1991. A predictive model for the clearance of soluble phospholipase A2 during septic shock.J. Lab. Clin. Med(in press).Google Scholar
  45. 45.
    Davidson, F. F., E. A. Dennis, M. Powell, andJ. R. Glenney, Jr. 1987. Inhibition of phospholipase A2 by “lipocortins” and calpactins. An effect of binding to substrate phospholipids.J. Biol. Chem. 262:1698–1705.Google Scholar
  46. 46.
    Conricorde, K. M., andR. S. Ochs. 1989. Mechanism for the inhibitory and stimulatory actions of proteins on the a activity of phospholipase A2.Biochim. Biophys. Acta 1003:36–43.Google Scholar
  47. 47.
    Nakano, T., andH. Arita. 1990. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoids.FEBS Lett. 273:23–26.Google Scholar
  48. 48.
    Nakano, T., O. Ohara, H. Teraoka, andH. Arita. 1990. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells.FEBS Lett. 261:171–174.Google Scholar
  49. 49.
    Green, J. A., G. M. Smith, R. Buchta, R. Lee, K. Y. Ho, I. A. Rajkovic, andK. F. Scott. 1991. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.Inflammation 15:355–367.Google Scholar
  50. 50.
    Okusawa, S., J. A. Gelfand, T. Ikejima, R. J. Conolly, andC. A. Dinarello. 1988. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.J. Clin. Invest. 81:1162–1172.Google Scholar
  51. 51.
    Heath, M. F., D. Tighe, R. Moss, andE. D. Bennett. 1990. Relevance of serum phospholipase A2 assays to the assessment of septic shock.Crit. Care Med. 18:766–767.Google Scholar
  52. 52.
    Waxman, K. 1990. Pentoxifylline in septic shock.Crit. Care Med. 18:243–244.Google Scholar
  53. 53.
    Tighe, D., R. Moss, M. F. Heath, J. Hynd, andE. D. Bennett. 1989. Pentoxifylline reduces pulmonary leukostasis and improves capillary patency in a rabbit peritonitis model.Circ. Shock 28:159–164.Google Scholar
  54. 54.
    Rossignol, L., M. Plantavid, H. Chap, andL. Douste-Blazy. 1988. Effects of two methylxanthines, pentoxifylline and propenfylline on arachidonic acid metabolism in platelets stimulated by thrombin.Biochem. Pharmacol. 37:3229–3236.Google Scholar
  55. 55.
    Bessler, H., R. Gilgal, M. Djaldetti, andI. Zahavi. 1986. Effect of pentoxifylline on the phagocytic activity, cAMP levels and Superoxide anion production by monocytes and polymorphonuclear cells.J. Leukocyte Biol. 40:747–754.Google Scholar
  56. 56.
    Scott, K. F. 1991. Phospholipase A2: A new target for monoclonal antibody therapy in sepsis. Abstracts 2nd international congress on the immune consequences of trauma, shock and sepsis mechanisms and therapeutic approaches. Munich. 46.Google Scholar
  57. 57.
    Buchta, R., J. A.Green, G. M.Smith, and K.Scott. 1991.E. coli-induced septic shock in the baboon: An animal model for the evaluation of neutralising monoclonal antibodies to phospholipase A2. Abstracts 2nd international congress on the immune consequences of trauma and sepsis mechanisms and therapeutic approaches. Munich. 86.Google Scholar

Copyright information

© Plenum Publishing Corporation 1992

Authors and Affiliations

  • W. Pruzanski
    • 1
  • D. W. Wilmore
    • 2
  • A. Suffredini
    • 3
  • G. D. Martich
    • 3
  • A. G. D. Hoffman
    • 3
  • J. L. Browning
    • 4
  • E. Stefanski
    • 1
  • B. Sternby
    • 5
  • P. Vadas
    • 1
  1. 1.Inflammation Research GroupUniversity of TorontoTorontoCanada
  2. 2.Brigham and Women 's HospitalHarvard Medical SchoolBoston
  3. 3.Critical Care Medicine DepartmentNational Institutes of HealthBethesda
  4. 4.Department of Cell BiologyBiogen Inc.Cambridge
  5. 5.Department of Physiological ChemistryUniversity of LundLundSweden

Personalised recommendations